Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Cancer Channel
Reported December 1, 2011

Intensive Chemo Improves Survival in Lymphoma Patients

(Ivanhoe Newswire) – Younger lymphoma patients given a more intensive chemotherapy regimen combined with rituximab live much longer, and are more than twice as likely to remain in remission 4 years later, compared to patients given standard chemo.

Over the past decade, combined treatment with the monoclonal antibody rituximab and a standard chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has substantially improved outcomes in lymphoma patients younger than 60 years. But some patients still relapse after a complete response to treatment, and the optimum chemotherapy regimen to combine with rituximab has yet to be established. Recent studies suggest that intensive chemotherapy (higher doses with shortened intervals between treatments) might benefit younger patients with aggressive lymphomas.

This study, conducted by the Groupe d'Etude des Lymphomes de I'Adulte (GELA), randomly assigned 379 patients aged 18 years with early intermediate-stage diffuse large B-cell lymphoma (one of the most common and aggressive forms of non-Hodgkin's lymphoma) to receive either four cycles of dose-intensive chemotherapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus rituximab (R-ACVBP)* at 2 week intervals, or eight cycles of the standard treatment (R-CHOP) at 3 week intervals.

After 3 years, event-free survival (patients not experiencing unplanned treatment for lymphoma, disease progression or recurrence, or death) was significantly better for patients in the dose-intensive group compared with those receiving standard treatment (81% vs 67%), with the more intensive chemotherapy reducing the risk of experiencing an event by 44%.

Additionally, patients assigned to the intensified regimen had a 56% lower risk of death and were 52% less likely to experience disease progression compared with those given standard treatment.

But increasing the treatment intensity also significantly increased the likelihood of serious side effects. In particular, haematological and mucosal toxic effects were significantly more common in the dose-intense group, and a much higher proportion of patients experienced febrile neutropenia (38% vs 9%).

"Intensified immunochemotherapy with R-ACVBP represents an alternative to R-CHOP to improve survival in patients younger than 60 years with diffuse large B-cell lymphoma of low-intermediate risk," the authors were quoted as saying.

They conclude by calling for further research to identify subsets of patients who are more likely to benefit from this intensive regimen.

SOURCE: Lancet, published online November 24, 2011


Related Articles in Latest Medical News:

[ Back to Cancer Channel Home ]

MEDICAL ALERT!
Stay up to date on Cancer. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Most Recent Videos

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page
Advertisement

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News